GlaxoSmithKline Pakistan (Glaxo):Result Review: GLAXO 1QCY25 EPS Rs6.7 - By Sherman Research
Apr 25 2025
Sherman Securities
- GlaxoSmithKline Pakistan (Glaxo) announced 1QCY25 EPS of Rs6.7 versus EPS of 1.8 during the same period last year, up by massive 3.7xYoY. The jump in earning is primarily attributable to increase in gross margins to 34% (up 19ppts).
- During 1QCY25, the company’s topline remained flat at 15.6bn compared to same period last year mainly due decline in volume.
- Thanks to hike in prices and decline in raw material prices, Glaxo’s gross margin sharply increased to 34% during 1QCY25 versus 15% during same period last year.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low